abstract |
The present invention provides a novel crystalline form of Lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, a process for its preparation, AND pharmaceutical compositions comprising the novel polymorphic form of Lenvatinib mesylate as active ingredient, in admixture with pharmaceutical excipients. |